Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer

The CROWN study (N = 76) found that loratinib improved the intracranial objective response rate (iORR) (64.9% vs. 17.9%, p < 0.001) compared to clotozantinib. The Impower150 study found that in 802 stage IV patients, atelizumab, bevacizumab, carboplatin and paclitaxel (ABCP) therapy resulted in a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational medicine 2024-03, Vol.14 (3), p.e1639-n/a
Main Authors: He, Liuer, Nie, Xin, Gao, Jiayi, Yuan, Yue, Wang, Xue, Li, Xu, Guo, Fengzhu, Tang, Min, Zhang, Ping, Li, Lin
Format: Article
Language:English
Subjects:
Brain research
Cancer therapies
Chemotherapy
Conflicts of interest
Genes
Genetic Profile
Genomics
Humans
Immunotherapy
Letter to the Journal
Lung cancer
Lung Neoplasms - genetics
Metastasis
Mutation
Research funding
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The CROWN study (N = 76) found that loratinib improved the intracranial objective response rate (iORR) (64.9% vs. 17.9%, p < 0.001) compared to clotozantinib. The Impower150 study found that in 802 stage IV patients, atelizumab, bevacizumab, carboplatin and paclitaxel (ABCP) therapy resulted in a lower probability of developing new brain metastases in subsequent treatments compared to ACP therapy (7% vs. 12%, p = 0.017).8 ECOG-ACRIN E1505 revealed that in 1501 stage IB–IIIA patients, chemotherapy plus bevacizumab lead to a lower probability of developing new brain metastases in subsequent treatments compared to chemotherapy (6% vs. 10%, p = 0.02).9 This study is the first to explore MPHM. [...]generation EGFR TKI showed the best therapeutic effect on MPHM. Efficacy, safety, and health-related quality of life with camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced nonsquamous NSCLC with brain metastases (CAP-BRAIN): a
ISSN:2001-1326
2001-1326
DOI:10.1002/ctm2.1639